Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry
October 18, 2023 09:00 ET
|
Regeneron Pharmaceuticals, Inc.
NIH data show that globally less than 2% of genetic information being studied today originates from people of African ancestry1 The newly established Diaspora Human Genomics Institute (DHGI) will...
Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss
September 25, 2023 08:34 ET
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has successfully completed its acquisition of Decibel Therapeutics, Inc.,...
Regeneron Provides Update on Planned Chief Financial Officer Transition
September 08, 2023 16:46 ET
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Robert E. Landry, Executive Vice President, Finance and Chief Financial...
Regeneron Announces Updates to Board of Directors
September 08, 2023 16:45 ET
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Kathryn Guarini, Ph.D., and David P. Schenkein, M.D., have joined Regeneron’s...
An Old Dog with a New Trick… Ellodi’s APT-1011 Promises EoE Patients a Convenient and Potent Treatment Alternative
August 15, 2023 15:40 ET
|
Spherix Global Insights
Exton, Pennsylvania, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Since launching in May 2022, Sanofi/Regeneron’s Dupixent has been well received by gastroenterologists and allergists as an advancement for...
Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs
August 09, 2023 07:30 ET
|
Regeneron Pharmaceuticals, Inc.; Decibel Therapeutics, Inc.
Proposed acquisition builds on existing collaboration between Decibel and Regeneron, will accelerate and further resource key gene therapy programs for hearing loss Decibel’s lead investigational...
Regeneron Announces the 2023 Winners of The Regeneron Prize for Creative Innovation
August 01, 2023 07:00 ET
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 11th annual Regeneron Prize for Creative Innovation, a...
Regeneron Pharmaceuticals Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
July 25, 2023 15:04 ET
|
Block & Leviton LLP
BOSTON, July 25, 2023 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) for potential securities law violations. Investors who have lost money...
REGN Shareholder News: Johnson Fistel Encourages Regeneron Pharmaceuticals Shareholders with Losses to Contact the Firm Regarding Investigation
June 30, 2023 14:49 ET
|
Johnson Fistel, LLP
SAN DIEGO, June 30, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the...
Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations
May 25, 2023 17:00 ET
|
Regeneron Pharmaceuticals, Inc.
Data demonstrate objective response rates from 56% to 63% across three independent cohorts of advanced melanoma patients – about double the rate historically seen with anti-PD-1 alone in similar...